<?xml version="1.0" encoding="UTF-8"?>
<p>A total of 23/2326 (1%) studies investigated the economic burden of CHIKV, of which 19/23 (83%%) studied the economic burden of chikungunya disease in humans, 3/23 (13%) examined the cost-benefit of implemented vector control measures during epidemics and 1/23 (4%) reported the cost effectiveness of interventions to prevent the transmission of CHIKV through blood transfusions in Canada; 
 <xref rid="pone.0207554.t001" ref-type="table">Table 1</xref>, 
 <xref ref-type="supplementary-material" rid="pone.0207554.s010">S7 Table</xref>. Publications on the economic burden due to CHIKV were predominantly from countries impacted by major epidemics and used data collected from surveillance during epidemics to estimate costs [
 <xref rid="pone.0207554.ref122" ref-type="bibr">122</xref>, 
 <xref rid="pone.0207554.ref182" ref-type="bibr">182</xref>, 
 <xref rid="pone.0207554.ref269" ref-type="bibr">269</xref>â€“
 <xref rid="pone.0207554.ref271" ref-type="bibr">271</xref>]. The epidemics from these areas were reported to have high attack rates, case fatalities and many severe long term sequelae, posing a burden to healthcare systems. All but one study were published after 2005; 
 <xref ref-type="supplementary-material" rid="pone.0207554.s010">S7 Table</xref>. The 1980 study from Fiji calculated the cost effectiveness of vector control mitigation strategies in general [
 <xref rid="pone.0207554.ref272" ref-type="bibr">272</xref>].
</p>
